Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) FCF Margin (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed FCF Margin for 15 consecutive years, with 15.44% as the latest value for Q4 2025.

  • Quarterly FCF Margin fell 578.0% to 15.44% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.16% through Dec 2025, up 547.0% year-over-year, with the annual reading at 0.16% for FY2025, 547.0% up from the prior year.
  • FCF Margin for Q4 2025 was 15.44% at Gyre Therapeutics, down from 13.0% in the prior quarter.
  • The five-year high for FCF Margin was 360.88% in Q4 2021, with the low at 1777.65% in Q2 2021.
  • Average FCF Margin over 5 years is 303.94%, with a median of 3.93% recorded in 2024.
  • The sharpest move saw FCF Margin tumbled -163089bps in 2021, then surged 155243bps in 2023.
  • Over 5 years, FCF Margin stood at 360.88% in 2021, then crashed by -88bps to 41.67% in 2022, then crashed by -91bps to 3.82% in 2023, then plummeted by -353bps to 9.66% in 2024, then tumbled by -60bps to 15.44% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 15.44%, 13.0%, and 6.73% for Q4 2025, Q3 2025, and Q2 2025 respectively.